

## Taiwan-based startup Primo Biotech partners with SHINE Technologies to advance precision cancer care in APAC

09 January 2025 | News

## Partnership delivers advanced radioligand treatments across Asia-Pacific



Taiwan-based startup Primo Biotechnology has announced a strategic partnership with US-based SHINE Technologies, LLC, a global leader in nuclear medicine production.

The partnership includes a supply and exclusive distribution agreement to introduce Ilumira (n.c.a. lutetium-177, Lu-177), SHINE's high-purity therapeutic isotope, to Taiwan and the broader Asia-Pacific (APAC) market.

This collaboration is set to strengthen Primo's market presence, accelerate advancements in radioligand theranostics (RLT), and usher the region into the next era of precision medicine.

Ilumira represents a significant breakthrough in nuclear medicine. As a key innovation in radioligand therapy, this isotope provides patients with more precise and effective treatment options, particularly for hard-to-treat tumors. By addressing the growing demand for advanced cancer therapies, Primo aims to deliver comprehensive solutions from early diagnosis to late-stage treatment, further enhancing healthcare outcomes across the Asia-Pacific region.

This partnership reinforces the collaborative relationship between Primo and SHINE, enhancing their competitive edge in the Asia-Pacific region and globally. Under the agreement, Primo secures exclusive distribution rights for Ilumira in Taiwan, along with sales rights in Japan, South Korea, and Singapore. Primo will also have priority access to SHINE's other therapeutic isotopes, ensuring a reliable supply for emerging nuclear medicine therapies.

SHINE's Cassiopeia facility, located in Janesville, Wisconsin, serves as North America's largest production site for n.c.a. Lu-177. Currently expanding its capacity, the facility aims to double its annual output from 100,000 to 200,000 doses to meet the surging global demand for nuclear medicine. This production increase is expected to solidify SHINE's position as a leading supplier and provide a robust foundation for Primo's regional growth.